Adicet Bio Discloses Q2 2025 Financial Data and Offers Business Insights
Adicet Bio, a biotech company focused on cellular immunotherapies, is making significant strides in the development of its treatments. The company is prioritizing the development of ADI-212 for prostate cancer, while simultaneously progressing with the Phase 1 clinical trial of ADI-001 in autoimmune diseases.
ADI-001 in Autoimmune Diseases
The Phase 1 clinical trial for ADI-001 is currently enrolling patients across multiple autoimmune indications, including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS), and anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV). The trial consists of four separate arms grouping these diseases for treatment evaluation, with patients receiving a single dose of ADI-001.
Notably, the first SSc patient in the second cohort was dosed by July 2025, marking a key milestone. The trial's primary focus is evaluating safety and tolerability, with secondary assessments of pharmacodynamics, cellular kinetics, autoantibody changes, and disease activity at various follow-up points up to 24 months. Adicet Bio plans to share preliminary clinical data from the Phase 1 trial in the second half of 2025.
ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy targeting B-cells via an anti-CD20 CAR. It has received FDA Fast Track Designation for relapsed/refractory class III or IV LN, refractory SLE with extrarenal involvement, and SSc.
ADI-212 for Prostate Cancer
Adicet Bio is also advancing the development of ADI-212, an optimized next-generation gene-edited and armored clinical candidate designed to enhance potency in solid tumors and to deliver multiple anti-tumor mechanisms of action to the tumor microenvironment. The company expects to submit a regulatory filing for ADI-212 for the treatment of metastatic castration-resistant prostate cancer in the first quarter of 2026.
Financial Update
For the three months ended June 30, 2025, Adicet Bio reported a net loss of $31.2 million, compared to a net loss of $29.9 million during the same period in 2024. The company reduced its workforce by approximately 30% in connection with its strategic pipeline prioritization, which is expected to extend Adicet Bio's cash runway into the fourth quarter of 2026.
R&D expenses for the same period were $28.4 million, an increase from $25.9 million during the same period in 2024. The increase was due to a $1.4 million increase in expenses related to contract development and manufacturing organizations and contracted R&D services, a $1.6 million increase in facility-related expenses, and a $0.2 million increase in lab supplies and materials.
G&A expenses for the three months ended June 30, 2025 were $4.0 million, a decrease from $6.9 million during the same period in 2024. The decrease was due to a $1.8 million decrease in payroll and personnel expenses primarily related to a decrease in stock-based compensation expense and a $1.1 million decrease in facility-related expenses.
Adicet Bio has cash, cash equivalents and short-term investments of $125.0 million as of June 30, 2025, compared to $176.3 million as of December 31, 2024. The company expects that this amount will be sufficient to fund its operating expenses into the fourth quarter of 2026.
In a recent development, Adicet Bio has decided to discontinue the development of ADI-270 for patients with metastatic/advanced clear renal cell carcinoma and close enrollment in the ADI-270 Phase 1 clinical trial.
In conclusion, Adicet Bio is making significant strides in the development of its treatments, with the Phase 1 clinical trial for ADI-001 in autoimmune diseases ongoing and preliminary data expected in the latter half of 2025. The company is also prioritizing the development of ADI-212 for prostate cancer, with a regulatory filing expected in the first quarter of 2026.
The Phase 1 clinical trial for ADI-001, an investigational allogeneic gamma delta CAR T cell therapy, is currently enrolling patients with a variety of autoimmune conditions like lupus nephritis, systemic sclerosis, and systemic lupus erythematosus. Adicet Bio is also working on ADI-212, a treatment for metastatic castration-resistant prostate cancer, and plans to submit a regulatory filing for it in the first quarter of 2026.
